Clinical evidence
PrismRA® accurately identified patients who are unlikely to respond to TNFi therapies1-3
PrismRA was studied in biologic-naïve and biologic-exposed
patients in multiple cohorts (N=730 patient samples)
PrismRA can improve patient response rates by up to 38% by accurately stratifying patients prior to starting or changing therapy1,4
Finding the right medication faster helps your patient avoid unnecessary costs, dose escalations, and exposure to drugs unlikely to provide adequate therapeutic effect.
By strategically selecting therapies using PrismRA, you can avoid wasted time and leverage the window when intervention is most impactful.5
Response is defined as ACR50 at 6 months.
Guided by genomic information
The PrismRA biomarker panel relies on complex analysis of:1
Like fingerprints, molecular signatures are unique. They reveal how diseases affect each patient differently. A molecular signature combines a set of biological features to capture an individual’s genetic makeup and disease behavior. These features include RNA, proteins, and other features that reflect a patient’s distinctive disease biology.
